A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Inclusion Criteria

• •At an increased risk for a first MACE (i.e., no prior major ASCVD event), defined as any one of the following:
• •1. Evidence of atherosclerotic coronary artery disease (CAD) on computer tomography (CT) or invasive coronary angiogram defined as a coronary artery stenosis ≥20% but \<50% in the left main coronary artery or stenosis ≥20% but \<70% in any other major epicardial coronary artery, or
• •2. Coronary artery calcium (CAC) score obtained by CT-scan ≥100 Agatston units, or
• •3. High 10-year ASCVD risk ≥20%, or
• •4. Intermediate 10-year ASCVD risk 7.5% - \<20% with at least 2 risk-enhancing factors.
• •LDL-C ≥70 mg/dL (≥1.81 mmol/L) but \<190 mg/dL (\<4.91 mmol/L) at the screening visit. If on a background lipid lowering therapy, the dose should be stable for at least 4 weeks prior to the screening visit and the participant should be willing to remain on this background therapy for the entire duration of the study.